Suzanne Fuqua on Biopsying Metastatic Tumors

Suzanne A. W. Fuqua, PhD
Published: Friday, Oct 18, 2013

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, says that it is an exciting time for the treatment of patients with metastatic breast cancer.

Many women today are consenting to biopsy their metastatic lesions, which is the only way to learn about the mechanisms that evolve during the course of treatment. A metastatic tumor is not the same as a primary tumor, Fuqua says, as it evolves both with and as a function of treatment.

Biopsied lesions allow for the discovery of many new mechanisms of resistance that are targetable. Fuqua says that there are drugs available today that can be combined with hormonal therapies in this space.

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, says that it is an exciting time for the treatment of patients with metastatic breast cancer.

Many women today are consenting to biopsy their metastatic lesions, which is the only way to learn about the mechanisms that evolve during the course of treatment. A metastatic tumor is not the same as a primary tumor, Fuqua says, as it evolves both with and as a function of treatment.

Biopsied lesions allow for the discovery of many new mechanisms of resistance that are targetable. Fuqua says that there are drugs available today that can be combined with hormonal therapies in this space.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x